Guardant Health and Trial Library team up to improve cancer trial access using AI and genomic data. Discover how this could reshape enrollment and equity in oncology.
FDA clears Prilenia’s PREVAiLS ALS trial. Can pridopidine validate neuroprotection and shift the treatment paradigm? Read the full analysis here.
Pfizer’s tucatinib combo extends progression-free survival in HER2+ metastatic breast cancer. Find out what HER2CLIMB-05 means for frontline maintenance therapy.
GE HealthCare and Tribun Health join forces to unify cancer diagnostics at Sant’ Andrea Hospital. See how digital pathology is reshaping oncology workflows.
IDEAYA Biosciences files IND for IDE574, a KAT6/7 inhibitor for breast and lung cancer. Learn how this new class may change epigenetic treatment strategies.
Ascletis' acne drug denifanstat advances with NDA acceptance in China. Explore how FASN targeting could disrupt acne care and redefine systemic treatments.
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.
Can four doses replace chronic ITP therapy? Find out how Novartis’ ianalumab performed in the VAYHIT2 trial and what it could mean for autoimmune care.
TrilliumBiO and Oncobit launch a ctDNA-based monitoring platform for uveal melanoma in the U.S. Learn how this could change rare cancer care in 2026.
Guardant Health brings its Guardant360 CDx test to Policlinico Gemelli in Italy. Find out how in-house liquid biopsy could reshape cancer diagnostics in Europe.